Rex Fang & Innovation Equity Premium Income ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $42.06 (market cap $735.35M), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.93 (market cap $10.69B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 14.5× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 58 Days and Dr. Reddy's Laboratories Ltd Common Stock for 1 Days on average.
| FEPI | RDY | |
|---|---|---|
Market Cap | $735.35M | $10.69B |
Volume | 465,088 | 2,546,816 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $15.38 |
52-Week Low | $37.98 | $11.38 |
Typical Hold Time | 58 Days | 1 Days |
Enterprise Value | — | $10.59B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $42.08, down 2.77% with a bearish technical outlook. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating weekly dividends but facing criticism for capped upside and elevated risk. Recent articles highlight its 25% yield but note underperformance compared to peers in total return and drawdown protection during market volatility.
The outlook remains cautious due to concentrated tech exposure and reliance on options income. While the high yield attracts income investors, risks include tech sector volatility and strategy limitations during rallies. Analyst sentiment is neutral to bearish, with concerns about sustainable returns if AI momentum slows.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →